Form 8-K - Current report:
SEC Accession No. 0001367644-22-000152
Filing Date
2022-12-06
Accepted
2022-12-06 07:01:24
Documents
17
Period of Report
2022-12-06
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ebs-20221206.htm   iXBRL 8-K 35933
2 EX-99.1 narcanotcfilingacceptanc.htm EX-99.1 12288
7 narcanotcfilingacceptanc001.jpg GRAPHIC 274309
8 narcanotcfilingacceptanc002.jpg GRAPHIC 251473
9 narcanotcfilingacceptanc003.jpg GRAPHIC 82632
  Complete submission text file 0001367644-22-000152.txt   1044524

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ebs-20221206.xsd EX-101.SCH 2218
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ebs-20221206_def.xml EX-101.DEF 2933
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ebs-20221206_lab.xml EX-101.LAB 27198
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ebs-20221206_pre.xml EX-101.PRE 14705
11 EXTRACTED XBRL INSTANCE DOCUMENT ebs-20221206_htm.xml XML 11025
Mailing Address 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879
Business Address 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879 240-631-3200
Emergent BioSolutions Inc. (Filer) CIK: 0001367644 (see all company filings)

EIN.: 141902018 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33137 | Film No.: 221446677
SIC: 2834 Pharmaceutical Preparations